BACKGROUND: Available evidence on the prognostic role of procalcitonin levels in acute coronary syndromes (ACS) is so far controversial. AIMS: To evaluate the association between procalcitonin, major cardiovascular events (MACE) and total mortality in acute coronary syndromes. METHODS: Procalcitonin levels were measured in 247 patients admitted to our Intensive Cardiac Care Unit (ICCU) with ACS. Three subgroups were considered according to procalcitonin levels. RESULTS: At Cox regression analysis, procalcitonin levels were both an unadjusted and an adjusted predictor (corrected for diagnosis and TnI) of intra-ICCU mortality and of 1-year follow-up MACE and total mortality. CONCLUSIONS: In ACS, admission procalcitonin values identify a "higher risk" group of patients for short and long-term mortality.
BACKGROUND: Available evidence on the prognostic role of procalcitonin levels in acute coronary syndromes (ACS) is so far controversial. AIMS: To evaluate the association between procalcitonin, major cardiovascular events (MACE) and total mortality in acute coronary syndromes. METHODS: Procalcitonin levels were measured in 247 patients admitted to our Intensive Cardiac Care Unit (ICCU) with ACS. Three subgroups were considered according to procalcitonin levels. RESULTS: At Cox regression analysis, procalcitonin levels were both an unadjusted and an adjusted predictor (corrected for diagnosis and TnI) of intra-ICCU mortality and of 1-year follow-up MACE and total mortality. CONCLUSIONS: In ACS, admission procalcitonin values identify a "higher risk" group of patients for short and long-term mortality.
Authors: Antoine Kossaify; Annie Garcia; Sami Succar; Antoine Ibrahim; Nicolas Moussallem; Mikhael Kossaify; Gilles Grollier Journal: Biomark Insights Date: 2013-09-03